JAK2 and breast carcinoma: On the whole, activation of JAK2-STAT3 and JAK2-STAT5 downstream of IL-6R and PRLR, respectively, may play a coordinated role in the development and progression of luminal breast cancer, suggesting the importance of these signaling cascades in ER-positive breast tumors.